Iron chelation efficiency of deferasirox (Exjade®, ICL670) in patients with transfusional hemosiderosis

被引：0
|
作者：
Porter, J
Borgna-Pignatti, C
Baccarani, M
Saviano, A
Abish, S
Malizia, R
Nick, H
Opitz, H
Rabault, B
Gathmann, I
Marks, P
机构：
[1] Univ Coll Hosp, London, England
[2] Univ Ferrara, I-44100 Ferrara, Italy
[3] Policlin S Orsola, Bologna, Italy
[4] Azienda Ospe Rilievo Nazl A Cararelli, Naples, Italy
[5] Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada
[6] Azienda Ospe Villa Sofia, Palermo, Italy
[7] Novartis, Basel, Switzerland
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2690
引用
下载
收藏
页码：755A / 756A
页数：2
相关论文
共 50 条
  • [1] Comparative pharmacokinetic/pharmacodynamic profiles in Japanese and Caucasian patients with transfusional hemosiderosis ReceivingTreatment with deferasirox (Exjade®, ICL670).
    Iki, S.
    Urabe, A.
    Hata, T.
    Ohyashiki, K.
    Nakao, S.
    Takatoku, M.
    Ishikawa, T.
    Kato, J.
    Tatsumi, Y.
    Mori, H.
    Tanii, H.
    Taniguchi, J.
    Kondo, M.
    Schran, H.
    Rabault, B.
    BLOOD, 2006, 108 (11) : 296B - 297B
  • [2] Deferasirox (Exjade®, ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients
    Kattamis, C
    Kilinc, Y
    Fattoum, S
    Ferster, A
    Gallisai, D
    Maggio, A
    Dresse, MF
    Klingebiel, T
    Bourantas, K
    Canatan, D
    Maseruka, H
    Gathmann, I
    Ford, J
    BLOOD, 2005, 106 (11) : 756A - 756A
  • [3] Patient-reported outcomes of deferasirox (Exjade®, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis
    Vichinsky, Elliott
    Pakbaz, Zahra
    Onyekwere, Onyinye
    Porter, John
    Swerdlow, Paul
    Coates, Thomas
    Lane, Peter
    Files, Beatrice
    Mueller, Brigitta U.
    Coic, Lena
    Forni, Gian Luca
    Fischer, Roland
    Marks, Peter
    Rofail, Diana
    Abetz, Linda
    Baladi, Jean-Francois
    ACTA HAEMATOLOGICA, 2008, 119 (03) : 133 - 141
  • [4] Iron chelating efficacy is related to transfusional iron intake in pediatric patients-treated with deferasirox(Exjade®, ICL670)
    Kattarruis, A.
    Paley, C.
    PEDIATRIC BLOOD & CANCER, 2007, 48 (06) : 609 - 609
  • [5] Clinical evaluation of deferasirox (Exjade®, ICL670)
    Porter, John
    SEMINARS IN HEMATOLOGY, 2007, 44 (02) : S16 - S20
  • [6] Deferasirox (Exjade®, ICL670) preclinical overview
    Nick, Hanspeter
    SEMINARS IN HEMATOLOGY, 2007, 44 (02) : S12 - S15
  • [7] PK/PD profiles during deferasirox (Exjade®, ICL670) treatment are similar in Japanese and Caucasian patients with transfusional iron overload
    Iki, S.
    Urabe, A.
    Hata, T.
    Ohyashiki, K.
    Nakao, S.
    Takatoku, M.
    Ishikawa, T.
    Kato, J.
    Tatsumi, Y.
    Mori, H.
    Tanii, H.
    Taniguchi, J.
    Kondo, M.
    Schran, H.
    Rabault, B.
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (06) : 514 - 514
  • [8] Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis.
    Angelucci, E
    Turlin, B
    Canatan, D
    Mangiagli, A
    De Sanctis, V
    Meddeb, B
    Rose, C
    Soulieres, D
    Cunningham, M
    Gattermann, N
    Ressayre-Djaffer, C
    Rabault, B
    Ford, J
    BLOOD, 2005, 106 (11) : 757A - 758A
  • [9] Deferasirox (Exjade®, ICL670):: A journey into labile iron centers of living cardiomyocytes.
    Cabantchik, ZI
    Link, G
    Glickstein, H
    Ben El, R
    Hershko, C
    Konijn, AM
    Nick, H
    BLOOD, 2005, 106 (11) : 243A - 243A
  • [10] Iron parameters in 84 MDS patients enrolled in a deferasirox (Exjade®, ICL670) multicenter trial.
    List, Alan F.
    Esposito, Jason
    Decker, Jodie
    Baer, Maria R.
    Powell, Bayard
    Steensma, David
    Raza, Azra
    Terebelo, Howard
    Maciejewski, Jaroslaw
    Goldberg, Stuart L.
    Paley, Carole
    BLOOD, 2006, 108 (11) : 297B - 297B
12345